VaxInnate, Inc.

US biotech VaxInnate is gaining an additional $53m under its February 2011 contract with the Biomedical Advanced Research and Development Authority (BARDA) to develop vaccines against influenza. Cranb

Vivaldi Biosciences has inked a cooperative research and development agreement with the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to

US health officials said the death of a Canadian from the H5N1 influenza virus, confirmed on 9 January by the World Health Organization (WHO), poses a "very low" risk to other people in the Americas.

G1 Therapeutics, a privately held pharmaceutical company focused on the discovery and development of novel small molecules for use in cancer therapy and biodefense, has named Dr Seth Rudnick executive